Healthcare
Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference® 2026 (AAIC®)
Eisai Co., Ltd. announced today the company will present the latest findings from its Alzheimer's disease (AD) research, including lecanemab (brand name: LEQEMBI®), our anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD) and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer's Association International Conference® 2026 (AAIC®) from July 12-15 in London and online. Eisai will present 52 abstracts across its AD portfolio
About this update from Eisai Co., Ltd.
TOKYO, June 29, 2026 /PRNewswire/ -- Eisai Co., Ltd. announced today the company will present the latest findings from its Alzheimer's disease (AD) research, including lecanemab (brand name: LEQEMBI®), our anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD) and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer's Association International Conference® 2026 (AAIC®) from July 12-15 in London and online. Eisai will present 52 abstracts across its AD portfolio at AAIC. Highlights include a Developing Topics Session and a Featured Research Session on lecanemab, featuring four and six oral presentations, respectively, alongside 10 additional key oral presentations and 32 posters. Eisai will also host a symposium on early intervention in AD. Key PresentationsA Developing Topics Session will feature emerging clinical evidence and practical use considerations for the subcutaneous formulation of lecanemab, including clinical trial and real-world patient experience. A Featured Research Session will highlight data from the LEADER study evaluating real-world lecanemab use in diverse US clinical settings three years post-approval, including results on maintenance dosing with IV treatment every four weeks and the first reported findings of at-home subcutaneous administration. Presentations on the Phase 3 AHEAD 3-45 study in preclinical AD will highlight progress of the trial including updates on participant retention and engagement. Additional oral presentations will highlight a Phase 2 trial of etalanetug with background lecanemab, and the effect on tau pathology. "We are sharing a broad and robust data set at AAIC spanning the Alzheimer's disease continuum, multiple therapeutic targets, and modes of administration, underscoring our commitment to advancing care for this complex disease," said Lynn D. Kramer, M.D., FAAN, Chief Clinical Officer, Deep Human Biology Learning (DHBL), Eisai. "Growing real-world experience with lecanemab, along with insights from patients, care partners, and clinicians, continues to add to our understanding of the value of early intervention, long-term treatment, and patient choice in care delivery." AAIC 2026 Presentations Relating to Eisai's Key Compounds and Research Developing Topics Session #1-32-FRS-C: Lecanemab Subcutaneous Formulation in Early Alzheimer's Dise...